The BCR/ABL fusion gene originating from a t(9;22)(q34;q11.2) chromosomal translocation is the molecular marker of chronic myeloid leukemia (CML). In the vast majority of CML cases the breakpoint on ...

ORLANDO, Fla.—Hyperglycemia occurring during front-line treatment with nilotinib was usually mild, transient, manageable, and did not lead to treatment discontinuation in patients with chronic-phase ...

More news from the American Society of Hematology meeting: In the first head-to-head comparison of Novartis' Tasigna and its older medicine Glivec (also known as Gleevec), Tasigna results showed ...

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...